Critical Therapeutic Advances for Optimizing Clinical Outcomes in  

MAC LUNG DISEASE

Focus on ERS Guideline-Directed Use of Inhaled Antimicrobial Formulations for

NTM Pulmonary Disease

September, 2022 - ERS 2022 Virtual Symposium Post-Program Assessment Survey

Survey Instructions

This post-program survey is designed to determine the educational effectiveness of the virtual symposium you just viewed. Aggregate results from this Phase 2 survey will be compared with results from if the pre-program survey you topok before watching this educational porgram.

To complete this Post-Program Assessment Survey, select your answer for each of the questions below. Please select the answer that most accurately applies to each question.

All results of this survey will remain confidential. We will use a de-identifying numeric code to tabulate results, and the results of your individual responses will not be shared with any third party.

Thank you,
CMEducation Resources

Updated Post-Program, Self-Reported Knowledge and Understanding Levels for Pulmonologists, Infectious Disease Specialists, and Other Physicians Managing Patients with MAC Lung Disease After Viewing this ERS 2022 Virtual Satellite Symposium

1. Please evaluate the overall quality of this CME virtual symposium (Excellent - 5 to Unsatisfactory - 1) *
2. Please evaluate the effectiveness of the faculty in meeting the stated educational objectives of this CME virtual symposium (Excellent - 5 to Unsatisfactory - 1) *
3. How likely are you to make changes in your practice based on the information presented during this CME virtual symposium? (Very likely - 5 to Unlikely - 1) *
4. How soon will you incorporate the information from this CME virtual symposium into your practice? *
5. When managing patients with MAC Lung Disease, how has your clinical proficiency changed, specifically, managing patients with resistant, poorly responsive, or progressive disease, after viewing this CME activity? *
6. When managing patients with MAC Lung Disease, how has your clinical proficiency changed in regards to applying the Year 2020 ATS/IDSA/ERS/ESCMID guidelines to your real world patient care treatment plans after viewing this CME activity? *
7. With respect to the emerging role of amikacin liposomal inhalation suspension, the following best characterizes your knowledge and clinical proficiency in using this antimicrobial therapy in patients with MAC Lung Disease after viewing this CME activity: *
8. With respect to the mechanism-of-action (MoA) of amikacin liposomal inhalation suspension, the following best characterizes your knowledge of the MoA for this antimicrobial formulation after viewing this CME activity: *
9. With respect to identifying patients with MAC Lung Disease who, based on clinical trial data and FDA-approved indications, are appropriate candidates for amikacin liposomal inhalation suspension, the following best characterizes your knowledge of the clinical profiles that would make patients appropriate candidates for and likely to respond to such therapy after viewing this CME activity: *
10. With respect to your knowledge base of the microbial pathobiology and clinical trials evaluating the efficacy and safety of amikacin liposomal inhalation suspension, the following best characterizes your knowledge base after viewing this CME activity: *
11. With respect to your knowledge base of the clinical outcomes associated with various antimicrobial formulations, especially when used in MAC Lung Disease patients with severe, resistant, progressive and/or conversion-resistant disease, the following best characterizes your knowledge base after viewing this CME activity: *
12. How would you describe your understanding of the role of bronchiectasis, COPD, and TB as risk factors for MAC Lung Disease and the Implications for diagnosis and treatment after viewing this CME activity? *
13. With respect to your knowledge base regarding the evidence for prompt, intensive intervention in risk appropriate patients with MAC Lung Disease, the following best characterizes your knowledge base in terms of appropriate patient dialogue, risk assessment, detection of refractory disease, and determination of when antimicrobial treatment is more prudent than observation after viewing this CME activity: *
14. With respect to the evidence for prompt, intensive intervention in risk appropriate patients with refractory MAC Lung Disease, the following best characterizes your knowledge base and clinical proficiency in terms of the appropriate use of amikacin liposomal inhalation suspension in treating such patients after viewing this CME activity: *
15. Please indicate your practice type and setting. *
16. How many patients with MAC Lung Disease do you see in your practice each month? *
17. How often do you see/monitor patients with MAC Lung Disease? *

Your Information

Please provide your email address to complete this confidential survey form. Completed surveys will be assigned a de-identifying number that will allow us to process your survey responses and compare pooled pre-program survey results with post-program survey results to measure ongoing, enduring learning. Your email address will not be shared with any third parties. We may use your email addresses to conduct additional surveys and/or to communicate the aggregate final survey results to you. Thank you.

Powered byFormsiteReport abuse